Close Menu
  • Homepage
  • Local News
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
  • Business
  • Technology
  • Health
  • Lifestyle
Facebook X (Twitter) Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Facebook X (Twitter) Instagram Pinterest
JHB NewsJHB News
  • Local
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
Let’s Fight Corruption
JHB NewsJHB News
Home»Health»Obesity experts on risks of Wegovy, Ozempic weight loss drugs
Health

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

May 8, 2023No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Obesity experts on risks of Wegovy, Ozempic weight loss drugs
Share
Facebook Twitter LinkedIn Pinterest Email

Amid rising demand for medication like Wegovy, Ozempic, and Mounjaro that may result in important weight reduction, some weight problems specialists are involved concerning the medication’ prices — each to sufferers’ funds and to their well being.

Talking at a panel on new weight problems remedies on the STAT Breakthrough Summit in San Francisco on Thursday, one knowledgeable cited a big medical trial for Wegovy that confirmed that about 40% of the load members misplaced was lean mass. Uncomfortable side effects like nausea, vomiting, and a potential hyperlink to uncommon circumstances of pancreatitis additionally nonetheless plague this latest class of medicine, which imitate the consequences of a hormone referred to as glucagon-like peptide 1 (GLP) that helps individuals really feel full.

“That’s what hunger does. You lose equal quantities of muscle and fats,” mentioned Robert Lustig, emeritus professor of pediatrics on the College of California, San Francisco. “Should you’re an individual 60 years previous or over and also you’re dropping muscle, your threat of dying simply went up exponentially. So we could also be … robbing Peter to pay Paul.”

Jamy Ard, professor of epidemiology and prevention at Wake Forest College of Drugs, was extra open to utilizing the medication to deal with some individuals with weight problems. For sufferers who don’t really feel full as a result of their our bodies have a weaker GLP-1 response after consuming, Ard — additionally the co-director of a weight administration middle at Wake Forest — would possibly suggest an incretin.

“It’s like I’ve given you a distant management that lets you flip up the amount on the tv,” he mentioned.

That mentioned, the medication are pricey, as Ard acknowledged; Wegovy, for instance, has a median web value of $13,600 per yr. Which means they’ve the potential to make present well being disparities even worse. Folks most affected by social determinants of weight problems, resembling poverty and decreased entry to wholesome meals and areas for bodily exercise, are additionally these least prone to have entry to those remedies by means of medical health insurance or the flexibility to pay out of pocket.

On the identical time, public discourse round these latest medication helps break down one other main barrier to tackling weight problems, Ard mentioned — a longstanding view that “for those who simply assume laborious sufficient, for those who attempt laborious sufficient, then you may keep skinny or you may drop pounds and hold it off.”

The pharmaceutical corporations behind the brand new weight reduction medication, together with Novo Nordisk and Eli Lilly, have launched campaigns to get the general public to see weight problems as a illness. Ard pointed to analysis that reveals that weight points aren’t a matter of lack of willpower.

The medication “symbolize the evolution of our studying and understanding of the physiology associated to physique weight regulation,” mentioned Ard, who has consulted for corporations like Novo and Eli Lilly.

However Ard cautioned towards over-prescribing the medication, noting that the present frenzy over them dangers being “pushed not by supplier discretion and enter however actually on the social media facet [by] … points that aren’t associated to illness.”

Lustig, who can also be the chief medical officer of fiber complement startup BioLumen, mentioned that fixing entry points to wholesome meals needs to be prioritized earlier than turning to medication as an answer. He famous that in medical trials for medication like Mounjaro, affected person responses had been in contrast towards a placebo, however to not a gaggle that ate totally different meals. Decreasing the quantity of sugar in meals, he mentioned, might have a big effect on weight problems.

“Repair the meals first,” Lustig mentioned. “Let’s see if these medication are literally higher than actual meals.”

Learn extra of STAT’s collection on The Weight problems Revolution. Different elements of this collection study how pharmaceutical makers are selling a brand new message about weight problems; assess makes an attempt to personalize weight problems therapy; clarify the origins of a flawed weight metric, the physique mass index; and delve into the talk over new childhood weight problems tips.



Source link

drugs experts Loss obesity Ozempic risks Wegovy Weight
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Rupee posts biggest single-day loss in over 2 years. Here’s why | Business News

May 8, 2025

Karan Johar quashes Ozempic claims, opens up about thyroid fluctuations, eating one meal a day: ‘Maine kuch 1000 diets, 500 workout kiye hai’ | Food-wine News

May 8, 2025

‘Poor execution costed us the game’- Mahela Jayawardene on MI’s loss vs GT

May 7, 2025

Trump claims tariffs could ‘eliminate’ taxes for most of Americans, but experts argue the math doesn’t add up

May 6, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Diddy Mouths 3-Word Question To Pregnant Reporter During Trial

May 10, 2025

Pakistan gets IMF tranche but economy too stretched to sustain long standoff | Business News

May 10, 2025

Google May Pixel Drop: Phone Bug Fixes But a Warning

May 10, 2025

Tapestry lifts forecasts on booming demand for Coach handbags

May 10, 2025
Popular Post

Credit Market Investors are Watching for a Federal Reserve Pivot

“I don’t think the Lakers are gonna be a disaster the way they were last year” – NBA analyst predicts a healthy LeBron James and Anthony Davis could take Lakers to the Finals

Who is Yoshinobu Yamamoto, and why is he getting $325 million from the Dodgers?

Subscribe to Updates

Get the latest news from JHB News about Bangalore, Worlds, Entertainment and more.

JHB News
Facebook X (Twitter) Instagram Pinterest
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
© 2025 Jhb.news - All rights reserved.

Type above and press Enter to search. Press Esc to cancel.